Success Metrics

Clinical Success Rate
94.3%

Based on 33 completed trials

Completion Rate
94%(33/35)
Active Trials
0(0%)
Results Posted
52%(17 trials)
Terminated
2(5%)

Phase Distribution

Ph phase_3
29
78%
Ph phase_1
1
3%
Ph phase_2
1
3%
Ph phase_4
3
8%

Phase Distribution

1

Early Stage

1

Mid Stage

32

Late Stage

Phase Distribution34 total trials
Phase 1Safety & dosage
1(2.9%)
Phase 2Efficacy & side effects
1(2.9%)
Phase 3Large-scale testing
29(85.3%)
Phase 4Post-market surveillance
3(8.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.3%

33 of 35 finished

Non-Completion Rate

5.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

37

all time

Status Distribution
Completed(33)
Terminated(2)
Other(2)

Detailed Status

Completed33
Terminated2
Suspended1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
37
Active
0
Success Rate
94.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (2.9%)
Phase 21 (2.9%)
Phase 329 (85.3%)
Phase 43 (8.8%)

Trials by Status

suspended13%
unknown13%
completed3389%
terminated25%

Recent Activity

0 active trials
Showing 5 of 37
completedphase_3

Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)

NCT00156117
completedphase_3

Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)

NCT00156104
completedphase_3

Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)

NCT00212836
completedphase_3

9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)

NCT00143182
completedphase_3

3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)

NCT00159796
View all 37 trials

Clinical Trials (37)

Showing 20 of 37 trialsScroll for more
NCT00156117Phase 3

Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)

Completed
NCT00156104Phase 3

Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)

Completed
NCT00212836Phase 3

Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)

Completed
NCT00143182Phase 3

9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)

Completed
NCT00159796Phase 3

3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)

Completed
NCT00151424Phase 3

Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)

Completed
NCT00212784Phase 3

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)

Completed
NCT00159744Phase 3

3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)

Completed
NCT01244815Phase 3

Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)

Completed
NCT00764478Phase 3

Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)

Completed
NCT01617187Phase 3

A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)

Completed
NCT01244828Phase 3

Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)

Completed
NCT01142596Phase 3

Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)

Completed
NCT01349907Phase 3

Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)

Completed
NCT01190267Phase 3

Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)

Completed
NCT00145470Phase 3

12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)

Completed
NCT02893371

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
NCT00156091Phase 3

Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)

Completed
NCT00212771Phase 3

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)

Completed
NCT00159783Phase 3

40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
37